Illumina aims to push genetics beyond the lab with $200 genome – The Spokesman Review

Illumina Inc. says it can read a persons entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.

Illumina on Thursday unveiled a new line of DNA sequencing machines it says are twice as fast and accurate as its earlier models. Together, those upgrades will bring the cost per genome down two-thirds from its current technology, Chief Executive Officer Francis deSouza said.

Many consumers have been introduced to their DNA through relatively low-cost tests like those marketed by 23andMe Holding Co. that analyze small snippets of the genome for clues to disease risk and ancestry. Whole-genome sequencing can provide a far clearer, more accurate view of patients genetic makeup that doctors can use to precisely identify some diseases, including certain forms of cancer and heart disease. However, the price of performing the tests, along with their interpretation, has been a barrier for many patients that companies have been trying to bridge.

More efficient machinery and materials reduce customer cost to sequencing one genome, or the complete set of genetic material, Illumina said, adding that costs would range from less than $200 per genome, with discounts for bulk use, to $240 for a higher-quality analysis. Slashing the price of reading DNA could allow the practice to move into the mainstream, where it might be used to better tailor medications or treatments to people or have other health benefits.

This will be a huge force in terms of significantly increasing accessibility to genomics in a number of ways, deSouza said in an interview ahead of the announcement. It will democratize access to genomics by allowing sequencing to be offered to hospitals and researchers at much lower prices.

Despite promises of personalized medical care for the masses, genetic data has mostly been confined to research settings in the 21 years since an international group of scientists published the first analysis of the human genome sequence, Eric Topol, founder and director of Scripps Research Translational Institute, recently wrote. Illumina sees its new sequencing machine as a way to change that. Every meaningful price drop has rapidly led to an increase in the number of people whose genes have been analyzed, deSouza said.

Illuminas new NovaSeq X series comes in two models, with the base machine costing $985,000 and a more advanced one at $1.25 million. The new sequencers also come with new features like a simpler interface that could allow people without advanced degrees to use the machines, deSouza said.

This is a crucial test for San Diego-based Illumina at a time of increased scrutiny from Wall Street. The company cut its full-year sales outlook last month, raising questions about demand. New competitors are cropping up and threatening Illuminas dominance of the sequencing market. Moreover, the companys years-long quest to acquire early-cancer detection company Grail is in limbo and facing regulatory challenges in Europe. Shares of Illumina have lost nearly half their value this year.

Already under a microscope, the company is hosting a splashy conference in its hometown this week to unveil the technology.

Investors are closely following the event for signs Illumina can change its story. Customers, mostly drug companies and research institutions, will be paying attention to price. Before the launch, nearly three dozen sequencing customers had estimated Illumina would set its prices at $280 per genome, according to a survey from Cowen analysts.

The new machines could have real financial implications for researchers who sequence large numbers of people, said Aris Baras, who leads Regeneron Pharmaceuticals Inc.s Genetics Center. Regeneron scours genetic data to discover new drug targets. Baras praised Illumina for continuously decreasing the price of sequencing, allowing Regeneron to screen about 2 million people.

Its a testament to Illuminas innovation pushing down costs and increasing output especially when they havent historically had too many competitors being able to match them, Baras said. Still, the price isnt low enough for Regeneron to switch to exclusively whole genome sequencing. The drugmaker mostly scans only genes of key interest, which costs between one-fifth and one-tenth the price of reading all of a persons genetic material.

Read the original post:
Illumina aims to push genetics beyond the lab with $200 genome - The Spokesman Review